ASPHF (Ascentage Pharma Group International) EPS (Basic): $-0.49 (TTM As of Dec. 2025)


ASPHF Ascentage Pharma Group International ASPHF
71 GF Score
Price $4.53
GF Value $6.61
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Ascentage Pharma Group International EPS (Basic)?

Ascentage Pharma Group International ASPHF -3.51% 71 EPS (Basic) is $-0.49 as of Dec. 2025. GuruFocus rates ASPHF with a GF Score™ of 71/100 and a GF Value™ of $6.61 (Possible Value Trap). The stock has 7 warning signs investors should review.

Ascentage Pharma Group International's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was $-0.25. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.49.

Ascentage Pharma Group International's EPS (Diluted) for the six months ended in Dec. 2025 was $-0.25. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.49.

Ascentage Pharma Group International's EPS without NRI for the six months ended in Dec. 2025 was $-0.25. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.49.

During the past 3 years, the average EPS without NRI Growth Rate was -0.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Ascentage Pharma Group International's highest 3-Year average EPS without NRI Growth Rate was 35.10% per year. The lowest was -176.60% per year. And the median was -0.40% per year.

Ascentage Pharma Group International  (OTCPK:ASPHF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Ascentage Pharma Group International EPS (Basic) Related Terms

Ascentage Pharma Group International EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Ascentage Pharma Group International's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascentage Pharma Group International EPS (Basic) Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 -0.48 -0.46 -0.18 -0.50

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 0.08 -0.26 -0.24 -0.25
ASPHF
71GF Score
Ascentage Pharma Group International ASPHF
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascentage Pharma Group International EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Ascentage Pharma Group International's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-176.449-0)/356.130
=-0.50

Ascentage Pharma Group International's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-92.572-0)/370.670
=-0.25

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.49 mean?
Ascentage Pharma Group International (ASPHF) has a EPS (Basic) of $-0.49 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Ascentage Pharma Group International and its competitors.
Is Ascentage Pharma Group International's EPS (Basic) too high?
Ascentage Pharma Group International's current EPS (Basic) is $-0.49. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's EPS (Basic) compare to VRTX and REGN?
Ascentage Pharma Group International's EPS (Basic) of $-0.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Ascentage Pharma Group International and its competitors. Ascentage Pharma Group International's current EPS (Basic) is $-0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current EPS (Basic) is $-0.49. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current EPS (Basic) is $-0.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61. GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.

Key valuation signals for ASPHF:

  • EPS (Basic): $-0.49
  • GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
  • GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ascentage Pharma Group International Business Description

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score

Get the complete analysis for ASPHF

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53
Price
$6.61
GF Value